ALNY Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. (ALNY) trend channel, buy level and 3-month target on Trade The Path. Sector: Healthcare. Listed on NASDAQ. Levels below are fitted to this ticker's own swing highs and lows (Theil–Sen, log-price), then projected 3 months. If this ticker has no settled sample yet, treat the numbers as a geometric read, not a track record. Information only, not financial advice.
Broken down below, falling on both timeframes
Price has closed below the channel. Support has failed — treat the buy target with caution.
Read from the last 12 months of history we hold: falling, drifting −51% a year. The nearest ceiling overhead is US$352.30. What would overturn this: a close below US$256.56 — the floor of the channel being read — after which the trend, not the entry, is what was wrong.
- 12 months read from
- US$256.49 – US$352.30 Falling channel, −51% a year
- Position in that channel
- -18% below the floor of it — 0% is the floor, 100% the ceiling
What broke this trend
- The fall
- -58% from US$491.3420 Oct 2025 → 30 July 2026
- Whose problem it was
- This company0 of 2 Biotechnology peers fell with it
- Does it resolve?
- Unsettled too close to a coin toss on the record to call
- Regained so far
- 12%of what it lost
- What the record says
- 56% of 545 comparable falls came back, typically in 140 days measured across every stock we hold history for, its peer group being too small
The trend broke in October 2025: price fell 58% from 491.33 to 205.50 by July 2026, and has regained 12% of that fall since. Its peers did not fall with it, so this was about the company rather than its sector. The wire that week: “Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $535”. What happens next is not settled: falls of about 58% here have come back to the old high 56% of the time (545 comparable falls), typically in 140 days, which is too close to a coin toss to price a recovery from.
Reported at the time: Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $535 — 17 Oct 2025
Price history, with the path projected 3 months forward
- Daily close
- Upper trend line (12 months)
- Lower trend line (12 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
No published call today because price has broken 6.4% below the channel floor, which is a fall out of the trend rather than a dip within it. No alerts are sent. The buy and target below are still this site's read of the fitted channel.
Buy now
US$239.45
last close · 16 Sept 2026
Channel buy is US$256.46; last close is the better price available now.
Our target
US$321.25
by 16 Dec 2026
Projected move
34.2%
gross, before costs
Last close is our buy — the best price available now.
- Upper line touches
- 3
- Lower line touches
- 3
- Fit confidence
- 49%
- Fitted
- 16 Sept 2026
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy associated with hereditary transthyretin-mediated amyloidosis; GIVLAARI for adult patients with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for primary hyperoxaluria type 1 (PH1). Beyond its commercial portfolio, the company maintains an active development pipeline. Key investigational therapies include givosiran, aimed at adolescent patients with AHP; patisiran, being explored for transthyretin amyloidosis (ATTR) with cardiomyopathy; cemdisiran for complement-mediated disorders; ALN-AAT02 for AAT deficiency-associated liver disease; ALN-HBV02 for chronic hepatitis B virus infection; Zilebesiran for hypertension; and ALN-HSD for non-alcoholic steatohepatitis (NASH). Additionally, other candidates such as Fitusiran for hemophilia and bleeding disorders, Inclisiran for hypercholesterolemia, an expanded indication for lumasiran for advanced PH1 and recurrent kidney stones, and vutrisiran for ATTR amyloidosis (currently in Phase 3 clinical trials) are also progressing. Alnylam also engages in strategic alliances with other pharmaceutical leaders. Notable collaborations include those with Regeneron Pharmaceuticals, Inc., focused on discovering and developing RNAi therapeutics for ocular and CNS targets, and with Sanofi Genzyme for broader RNAi therapeutic development and commercialization efforts. Further licensing and partnership agreements are in place with entities such as Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. Established in 2002, Alnylam Pharmaceuticals maintains its corporate headquarters in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yvonne L. Greenstreet
- Employees
- 2,500
- Country
- US
Scorecard
Our own pillar scores, computed from the fundamentals below. They are not Morningstar ratings — that data is licensed and we do not redistribute it.
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$35.65B
- Enterprise value
- —
- Beta
- 0.28
- Avg volume
- 1.58M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 197.81-495.55
- Exchange
- NASDAQ
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted statistically to past swing highs and lows and projected forward on the assumption the same rhythm continues. It often does not. This is information, not advice.